Patients with adrenal incidentaloma (AI) and subclinical hypercortisolism (SH) show a high prevalence of cardiovascular risk factors and an increased prevalence and incidence of cardiovascular events. Furthermore, some recent data suggest that in these patients, the cardiovascular mortality is also increased. Unfortunately, to date, the diagnosis of SH is still a matter of debate, and, therefore, it is still not possible to address the treatment of choice (i.e. surgical or conservative approach) in many AI patients. Overall, the available data show that in AI patients with established SH the surgical removal of the adrenal mass causing SH can lead to the improvement of hypertension and diabetes, but in many patients with possible SH the effect of surgery is still largely unknown. Finally, no data are available on the effect of the recovery from SH on the cardiovascular events. Therefore, randomized studies are needed to investigate the possibility of predicting the usefulness of surgery by using the available indexes of cortisol secretion in the individual AI patient. Finally, the development of safe and well-tolerated drugs aimed to control cortisol secretion will be among the goals of the future research.
Cardiovascular mortality in patients with subclinical Cushing = Mortalité cardiovasculaire dans les syndromes de Cushing infracliniques / V. Morelli, M. Arosio, I. Chiodini. - In: ANNALES D'ENDOCRINOLOGIE. - ISSN 0003-4266. - 79:3(2018 Jun), pp. 149-152. [10.1016/j.ando.2018.03.005]
Cardiovascular mortality in patients with subclinical Cushing = Mortalité cardiovasculaire dans les syndromes de Cushing infracliniques
V. Morelli;M. Arosio;I. Chiodini
2018
Abstract
Patients with adrenal incidentaloma (AI) and subclinical hypercortisolism (SH) show a high prevalence of cardiovascular risk factors and an increased prevalence and incidence of cardiovascular events. Furthermore, some recent data suggest that in these patients, the cardiovascular mortality is also increased. Unfortunately, to date, the diagnosis of SH is still a matter of debate, and, therefore, it is still not possible to address the treatment of choice (i.e. surgical or conservative approach) in many AI patients. Overall, the available data show that in AI patients with established SH the surgical removal of the adrenal mass causing SH can lead to the improvement of hypertension and diabetes, but in many patients with possible SH the effect of surgery is still largely unknown. Finally, no data are available on the effect of the recovery from SH on the cardiovascular events. Therefore, randomized studies are needed to investigate the possibility of predicting the usefulness of surgery by using the available indexes of cortisol secretion in the individual AI patient. Finally, the development of safe and well-tolerated drugs aimed to control cortisol secretion will be among the goals of the future research.File | Dimensione | Formato | |
---|---|---|---|
Cardiovascular mortality in patients with subclinical Cushing - Ann Endocrinol (Paris) 2018.pdf
accesso riservato
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
210.53 kB
Formato
Adobe PDF
|
210.53 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
1-s2.0-S0003426618300301-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
169.23 kB
Formato
Adobe PDF
|
169.23 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.